News Releases

Year

09 May '22

Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--May 9, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022

05 May '22

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500 ) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS Results also show 43% CBR in solid

20 Apr '22

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Data show PKMYT1 inhibition is a promising therapeutic target in CCNE1-amplified cancers RP-6306 , a first-in-class, oral PKMYT1 inhibitor, is currently being evaluated in Phase 1 clinical trials CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Apr. 20, 2022-- Repare Therapeutics Inc.

11 Apr '22

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

RP-3500 shows robust activity in ovarian cancer demonstrating 75% CBR, with 25% ORR and mPFS of 35 weeks Updated monotherapy results show 43% CBR in solid tumors across genotypes, and potential best-in-class safety and tolerability Encouraging data in tumors harboring STEP 2 genes, including

08 Apr '22

Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

Comprehensive Phase 1 monotherapy data from the phase 1/2 TRESR trial will be presented at AACR on Monday, April 11, 2022 at 3:05 p.m. CT Company to host conference call on Monday, April 11, 2022 at 6:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Apr. 8, 2022-- Repare Therapeutics Inc.

08 Mar '22

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 8, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

07 Mar '22

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress

Dose optimization provides robust evidence to advance RP-3500 into Phase 2 studies with a recommended dose and schedule CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 7, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology

01 Mar '22

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 1, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

03 Feb '22

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Feb. 3, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

07 Jan '22

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 7, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12